Trevena Inc. (TRVN) |
|
2.99 0.01 (0.34%)
|
10-01 09:24 |
|
Open: |
2.96 |
Pre. Close: |
2.98 |
|
High:
|
3.03 |
Low:
|
2.87 |
|
Volume:
|
5,073,640 |
Market Cap:
|
459M |
|
|
|
|
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 29 full-time employees. The firm is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. The company is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. The company is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. The company is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.034 - 3.046 |
3.046 - 3.058 |
|
Low:
|
2.84 - 2.854 |
2.854 - 2.866 |
|
Close:
|
2.968 - 2.99 |
2.99 - 3.01 |
|
Technical analysis |
as of: 2020-09-30 4:47:17 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 3.68 One year: 4.30 |
| Support: |
Support1: 2.11  Support2: 1.47 |
| Resistance: |
Resistance1: 3.15 Resistance2: 3.68 |
| Pivot: |
2.51 |
| Moving Average: |
MA(5): 2.87 MA(20): 2.30
MA(100): 1.84 MA(250): 1.20 |
| MACD: |
MACD(12,26): 0.27 Signal(9): 0.19 |
| Stochastic oscillator: |
%K(14,3): 85.15 %D(3): 81.56 |
| RSI: |
RSI(14): 71.55 |
| 52-week: |
High: 3.68 Low: 0.46 Change(%): 182.1 |
| Average Vol(K): |
3-Month: 1171430 10-Days: 981146 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.TRVN has closed below upper band by 21.2%. Bollinger Bands are 103.2% wider than normal. The large width of the bands suggest high volatility as compared to TRVN's normal range. The bands have been in this wide range for 8 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Wed, 30 Sep 2020
Trevena's Shares March Higher, Can It Continue? - Yahoo Finance
Wed, 30 Sep 2020
Here is why Trevena Inc. (TRVN) recent weekly performance of 4.20% shouldn’t bother you at All - The InvestChronicle
Tue, 29 Sep 2020
The Rejuvenation of Trevena Inc. (NASDAQ:TRVN) - The Oracle Dispatch
Fri, 25 Sep 2020
Should You Buy Trevena Inc (TRVN) Stock? - InvestorsObserver
Mon, 21 Sep 2020
A Little Luck Can Go a Long Way with Trevena Inc. (TRVN) as it 5-day change was 46.07% - News Daemon
Mon, 21 Sep 2020
Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
153 |
| Shares Float (M) |
130 |
|
% Held by Insiders
|
3.06 |
|
% Held by Institutions
|
20.53 |
|
Shares Short (K)
|
13,620 |
|
Shares Short P. Month (K)
|
8,620 |
Stock Financials |
|
EPS
|
-0.274 |
|
EPS Est This Year
|
-1.360 |
|
EPS Est Next Year
|
-0.930 |
|
Book Value (p.s.)
|
0.440 |
|
Profit Margin
|
|
|
Operating Margin
|
-88183.87 |
|
Return on Assets (ttm)
|
-26.0 |
|
Return on Equity (ttm)
|
-55.2 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.175 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-25 |
|
Levered Free Cash Flow (M)
|
-15 |
Stock Valuations |
|
PE Ratio
|
-10.91 |
|
PEG Ratio
|
|
|
Price to Book value
|
6.80 |
|
Price to Sales
|
14792.78 |
|
Price to Cash Flow
|
-18.72 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
